公司动态 - 公司宣布启动Efruxifermin (EFX)的第三阶段SYNCHRONY Outcomes试验，针对代谢功能障碍相关脂肪性肝炎(MASH)引起的代偿性肝硬化(F4)患者[1] - 公司在2024年欧洲肝脏研究协会(EASL)大会上展示了EFX的海报和最新口头报告[1] - 公司任命Scott Gangloff为首席技术官，加强领导团队[1] 临床试验进展 - 公司启动了SYNCHRONY计划的第三阶段临床试验，包括三个全球随机双盲安慰剂对照试验，旨在支持EFX用于治疗MASH引起的代偿性肝硬化和早期肝硬化MASH的上市申请[4] - SYNCHRONY Outcomes试验招募代偿性肝硬化(F4)患者，评估EFX 50mg每周注射的效果，主要终点是96周治疗后纤维化减退且MASH未恶化[4] - SYNCHRONY Histology试验招募早期肝硬化MASH(F2-F3)患者，评估EFX 28mg和50mg的效果，主要终点是52周治疗后纤维化改善和MASH/NASH的解决[4] - SYNCHRONY Real-World试验招募MASH或MASLD患者，评估EFX 50mg的安全性和耐受性[4] 财务更新 - 截至2024年6月30日，公司持有现金、现金等价物及短期和长期市场证券共计8.483亿美元[9] - 公司预计现有资金足以支持SYNCHRONY Histology和Real-World研究的主要终点读出，以及当前运营计划至2027年下半年[9] - 2024年第二季度研发费用为5530万美元，较2023年同期增长97.5%，主要由于多个临床试验的完成和启动，以及临床供应品的生产[9] - 2024年第二季度总运营费用为6570万美元，较2023年同期增长84.5%，包括研发和行政费用的增加[9] 产品介绍 - Efruxifermin (EFX)是公司的主要候选产品，用于治疗MASH，是一种Fc-FGF21融合蛋白，旨在模拟天然FGF21的生物活性，改善肝脏脂肪和炎症，逆转纤维化，增加胰岛素敏感性和改善脂质代谢[10][11] 行业背景 - 代谢功能障碍相关脂肪性肝炎(MASH)是一种严重的MASLD形式，估计影响超过1700万美国人，其特点是肝脏脂肪过量积累，导致肝细胞损伤、炎症和纤维化，可能进展为肝硬化、肝衰竭、癌症和死亡[12]

NEW YORK, July 17, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Akero Therapeutics, Inc. (NASDAQ: AKRO) on behalf of the company's shareholders. The investigation seeks to determine whether Akero's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of Akero Therapeutics, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjlfir ...

Akero Therapeutics, Inc. (AKRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power ...

LOS ANGELES, June 25, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ: AKRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 13, 2022 and October 9, 2023, inclusive (the "Class Per ...

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

SAN DIEGO, June 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Akero Therapeutics, Inc. (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, all dates inclusive (the “Class Period”), have until this Tuesday, June 25, 2024 to seek appointment as lead plaintiff. Captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), the Akero class action lawsuit charges Akero and certain of its top executive officers with ...

RADNOR, Pa., June 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) on behalf of investors who purchased or acquired Akero common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”).. The action charges Akero with violations of ...

NEW YORK, June 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of all purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 25, 2024.To join the Akero class action, go to https://rosenlegal.com/submit-form/?case_id=24557 or call Phill ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) common stock between September 13, 2022 and October 9, 2023, inclusive (the “Class Period”). If you suffered a loss on your Akero investments or would like to inquire about potentially pur ...